Deutsches Krebsforschungszentrum (DKFZ)
Location
Darmstadt | Germany
Job description
The German Cancer Research Center is the largest biomedical research institution in Germany. With more than 3,000 employees, we operate an extensive scientific program in the field of cancer research.
The Division of Cancer Genome Research is seeking a
Our division has a strong background in the analysis of genomic and epigenomic alterations in circulating DNA (cfDNA) and RNA from cancer patients (Angeles et al., 2022, 2023; Janke et al., 2022). In collaboration with partners at DKFZ, Heidelberg University and abroad, we use a broad spectrum of genomics and proteomics technologies to monitor tumor progression in samples from clinical studies.
To strengthen our team, we are looking for a postdoctoral scientist starting in April 2024.
Aufgaben:The division is a partner in several BMBF-funded cooperation projects investigating tumor heterogeneity in space and time. Our role in these projects is the systematic analysis of longitudinal liquid biopsies (plasma) to monitor tumor heterogeneity and subclonal composition over time using state-of-the-art genomic and proteomic technologies.
The successful candidate will use these technologies to identify and quantify genomic, transcriptomic and epigenomic changes in cfDNA samples from cancer patients. The postdoctoral scientist will apply panel-based ultra-deep NGS and shallow whole genome sequencing (sWGS) in order to determine single nucleotide and copy number variations as well as minimal residual disease under therapy. Global epigenomic sequencing of cfDNA will be performed to identify cellular origins and heterogeneity of the tumors. Microbiome profiling will be applied to determine the contribution of environmental and lifestyle factors to cancer development and progression. The data will be analyzed using the fully established framework of pertinent bioinformatic tools.
References:
Angeles AK, Janke F, Daum AK, Reck M, Schneider MA, Thomas N, Christopoulos P, Sültmann H. Integrated circulating tumor DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma. Brit J Cancer 129(1):112-121; Apr 29. doi: 10.1038/s41416-023-02284-0, 2023
Janke F, Angeles AK, Riediger AL, Bauer S, Reck M, Schneider MA, Muley T, Thomas M, Christopoulos P, Sültmann H. Monitoring progression of ALK-rearranged lung adenocarcinoma using DNA methylation patterns in cell free DNA. Clinical Epigenetics, 14(1):163; doi: 10.1186/s13148-022-01387-4, 2022
Angeles AK*, Christopoulos P*, Yuan Z, Bauer S, Janke F, Ogrodnik SJ, Reck M, Schlesner M, Meister M, Schneider MA, Dietz S, Stenzinger A, Thomas M, Sültmann H. Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis. NPJ Precision Oncology, 5(1):100; DOI 10.1038/s41698-021-00239-3, 2021
Qualifikationsprofil:Job tags
Salary
